tradingkey.logo
tradingkey.logo
Search

Mediwound Ltd

MDWD
Add to Watchlist
14.104USD
-0.166-1.16%
Market hours ETQuotes delayed by 15 min
181.27MMarket Cap
LossP/E TTM

Earnings Forecast

Currency: USD Updated: 2026-07-23
Previous score
8.33
Change
0
The current earnings forecast score of Mediwound Ltd is 8.33, ranking 42 out of 155 in the Pharmaceuticals industry. The average price target is 32.00, with a high of 39.00 and a low of 25.00.

Analyst Rating

Based on 6 analysts
Buy
Current Rating
30.167
Target Price
+111.25%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Mediwound Ltd
MDWD
6
Biogen Inc
BIIB
38
Amgen Inc
AMGN
37
Eli Lilly and Co
LLY
34
AbbVie Inc
ABBV
33
Pfizer Inc
PFE
32
1
2
3
...
32

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
Forecast
Actual

FAQs

What is Mediwound Ltd's expected revenue for the next quarter?

Mediwound Ltd's expected revenue is 2.59M.

What is Mediwound Ltd's price target?

Analysts forecast that Mediwound Ltd's price target is USD 32.00, with the highest forecast at USD 39.00 and the lowest forecast at USD 25.00.

How have Mediwound LtdMDWD's recent earnings per share performed?

The market expectation was USD -0.23, while Mediwound LtdMDWD's earnings per share (EPS) for the previous quarter was USD -0.56. EPS for the next quarter is expected at USD -0.76.

What is the analyst rating for Mediwound Ltd?

Based on the ratings of Mediwound Ltd's stock from 6 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.